Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs) have been associated with a lower incidence of diabetes mellitus in clinical trials of hypertensives and other high-risk patients. However, it is less clear if use of renin-angiotensin axis inhibitors lowers the risk of diabetes in patients with heart failure. In this issue of Circulation, Yusuf and colleagues analyze data from the CHARM trial to assess the risk of developing new-onset diabetes (a prespecified secondary outcome) in more than 5000 heart failure patients randomized to candesartan (an ARB) or placebo. The investigators report that candesartan use was associated with a 22% reduction in incidence of diabetes compared with placebo. The reduction in incidence of diabetes was consistent across clinical subgroups (age, sex, body mass index) and was particularly striking in patients with a relatively preserved ejection fraction. The authors emphasize that use of ARBs in heart failure patients provides added value by lowering the future risk of diabetes. See p 48.
STATIN TREATMENT AFTER ONSET OF SEPSIS IN A MURINE MODEL IMPROVES SURVIVAL, by Merx et al.
The clinical benefits achieved with HMG-CoA reductase inhibitors have been shown to extend well beyond the recognized lipid-lowering effects of these agents. The pleiotropic effects attributed to statins include increased bioavailable nitric oxide, increased antioxidant properties, inhibition of inflammatory responses, and improvement of endothelial dysfunction. Interestingly, investigators have recognized that these pleiotropic effects may be exploited to offer a therapeutic advantage in clinical situations other than atherothrombotic vascular disease. 
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Computed Tomography of the Coronary Arteries. See p e7.
